ARWR
HEALTHCAREArrowhead Pharmaceuticals Inc
$79.14+4.21 (+5.62%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ARWR Today?
No stock-specific AI insight has been generated for ARWR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.88$79.48
$79.14
Fundamentals
Market Cap$10.9B
P/E Ratio48.7
EPS$1.60
Dividend Yield—
Dividend / Share—
ROE0.8%
Profit Margin0.2%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding140.0M
ARWR News
22 articles- Arrowhead (ARWR) Q2 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Arrowhead Pharmaceuticals Q2 Earnings Call HighlightsMarketbeat·May 7, 2026
- Arrowhead Pharmaceuticals Swings to Fiscal Q2 Loss, Revenue Fallsmarketscreener.com·May 7, 2026
- ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q2 2026 EarningsQuiver Quantitative·May 7, 2026
- Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter ResultsYahoo Finance·May 7, 2026
- Arrowhead and Madrigal sign global licence for MASH RNAi therapyPharmaceutical-technology·May 6, 2026
- Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors?Yahoo Finance·May 6, 2026
- Madrigal outlays $1bn for Arrowhead’s siRNA MASH assetPharmaceutical-technology·May 5, 2026
- Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal PharmaceuticalsYahoo Finance·May 5, 2026
- Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH PipelineYahoo Finance·May 5, 2026
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 EventsYahoo Finance·May 4, 2026
- The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCSYahoo Finance·May 4, 2026
- Arrowhead (ARWR) Rated Buy on Metabolic Pipeline PotentialYahoo Finance·May 2, 2026
- Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)Yahoo Finance·May 1, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessingsPharmaceutical-technology·Apr 24, 2026
- Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in EuropeYahoo Finance·Apr 24, 2026
- This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher.Yahoo Finance·Apr 21, 2026
- Intel upgraded, Reddit initiated: Wall Street's top analyst callsYahoo Finance·Apr 21, 2026
- Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter ResultsYahoo Finance·Apr 20, 2026
- Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside PotentialYahoo Finance·Mar 29, 2026
- Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and ExpoYahoo Finance·Mar 28, 2026
All 22 articles loaded
Price Data
Open$75.21
Previous Close$74.93
Day High$77.22
Day Low$74.45
52 Week High$79.48
52 Week Low$12.88
52-Week Range
$12.88$79.48
$79.14
Fundamentals
Market Cap$10.9B
P/E Ratio48.7
EPS$1.60
Dividend Yield—
Dividend / Share—
ROE0.8%
Profit Margin0.2%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding140.0M
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—